North America dominates the
global therapeutic drug monitoring market
North America holds the dominant
position in Therapeutic
Drug Monitoring Market, owing to robust health care infrastructure, high
awareness for treatment regime and increasing patient awareness regarding
adverse drug reaction (ADR). According to 2013 survey by Medical Expenditure
Panel published in Scientific American, 1 in 7 American adult consume
Anti-Psychotic drug, a class of drugs which requires TDM. Stringent government
regulations regarding safe medication practices especially with drugs having
narrow therapeutic range would propel growth therapeutic drug monitoring.
Moreover, increasing adoption of instruments such as monitors and analytic
equipment, reagents, and diagnostics tools for drug monitoring is driving the
growth of therapeutic drug monitoring market.
However, difficulty in
reimbursement bars the widespread usage of TDM, as often the cost associated
with TDM is high. Furthermore, insufficient infrastructure and skilled manpower
is restraining the growth of the market in emerging economies.
Therapeutic drug monitoring is a
multidisciplinary practice of measuring drug amount in bloodstream to maintain
its effective concentration. It is used to maximize efficacy of drug, avoid
toxicity and adverse drug reactions (ADR), facilitate dose adjustment according
patient requirement, and to identify therapeutic failure. It is used especially
for drugs characterized by narrow therapeutic window, drugs that are highly
protein bound and those in which the metabolite might be toxic.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1241
Physicians and hospitals use
therapeutic drug monitoring to maximize the clinical benefits of the drug by
minimizing the toxic side effects thereby improving the quality of life for the
patients.
Personalized medicine and
advanced technologies such as assay performance and drug monitoring to fuel the
growth of therapeutic drug monitoring market
Personalized medicine is driving
the growth of therapeutic drug monitoring market, owing to increasing demand
for better treatment outcome with minimum side effects from the medication. For
instance, TDM is majorly used for anti-cancer drugs monitoring for which
standard guidelines are recommended by many oncology Journal and associations,
one of them being the European Journal of Oncology. Moreover, advanced
treatment therapies such pharmacogenomics, gene testing, and proteomics is further
expected to boost the growth of market. Increasing antimicrobial resistance is
one of the key factor driving the growth of TDM market. According to WHO
Factsheet 2017, antimicrobial resistance is one of the leading cause of death.
For instance, according to WHO factsheet, around 4,80,000 multi-drug resistance
TB cases were reported, which is creating an opportunity for physicians to
optimize or monitor the drug therapies through TDM.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/therapeutic-drug-monitoring-market-1241
Organ transplant procedures are
also propelling the growth of therapeutic drug monitoring market.
Immunosuppressant drugs are basic treatment for organ transplant to avoid
rejection of transplanted organ by body, which requires TDM to avoid ADR and
side effects. Asia Pacific is a promising region for organ transplant due to increased
awareness and infrastructure availability. According to Waters Corporation
Blog, China witnessed 35% y-o-y increase in organ transplant in the first 4
months of 2017. There is a growing trend of clinical research organizations
being shifted to cost effective Asia Pacific region for bioequivalence study of
generic drugs on account of low cost of processes in this region. Moreover,
advances in the field of biomedical technology such as nano biosensors and
implantable devices are expected to boost the growth of therapeutic drug
monitoring market. Advancement in tools for TDM such as assay kits,
chromatography columns, spectrometry, and alternative matrices such as
interstitial fluid provide continuous real time monitoring of the therapeutic
drug through Probe Scientific’s new MicroEye Technology.
Key players in the global
therapeutic drug monitoring market include Roche Diagnostics, Thermo Fisher
Scientific, Bio Rad Laboratories, Siemens Healthcare Diagnostics, Beckmann
Coulter, and Abbott Diagnostics. In 2016, Danaher Corporation, parent company for
Beckman Coulter acquired Cepheid at US$ 4 billion to strengthen company’s
diagnostic portfolio.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1241
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment